

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method of treating or preventing menorrhagia in a female individual, the method comprising administering to the individual at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor.
2. (Original) A method according to Claim 1 wherein the agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor prevents or reduces the binding of PGF<sub>2 $\alpha$</sub>  to the FP receptor.
3. (Previously Presented) A method according to Claim 1 wherein the agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor affects the interaction between PGF<sub>2 $\alpha$</sub>  and the FP receptor, or the interaction between the FP receptor and the associated G<sub>αq</sub> protein, thus inhibiting or disrupting a PGF<sub>2 $\alpha$</sub> -FP mediated signal transduction pathway.
4. (Previously Presented) A method according to any of Claim 1 wherein the agent is an antagonist of the FP receptor.
5. (Currently Amended) A method according to Claim 4 wherein the FP receptor antagonist is any one or more of PGF<sub>2 $\alpha$</sub>  dimethyl amide; PGF<sub>2 $\alpha$</sub>  dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro PGF<sub>2 $\alpha$</sub> ); phloretin; glibenclamide; ridogrel; PHG113; PCP-1 (rvkfkssqqhrqgrshhlem) (SEQ ID NO:1); PCP-2 (rkavlknlyklasqccgvhvislhiwelssiknslkvaaisespvaeksast) (SEQ ID NO:2); PCP-3 (clseeakearrindeierqlrrdkrdarre-NH<sub>2</sub>) (SEQ ID NO:3); PCP-4 (kdtiqlqlkeynlv-NH<sub>2</sub>) (SEQ ID NO:4); PCP-8 (ilghrdyk) (SEQ ID NO:5); PCP-10 (wedrfyll) (SEQ ID NO:6); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK) ; PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).
6. (Previously Presented) A method according to Claim 1 wherein the agent is an antagonist of PGF<sub>2 $\alpha$</sub> .
7. (Original) A method according to Claim 6 wherein the PGF<sub>2 $\alpha$</sub>  antagonist is an anti-PGF<sub>2 $\alpha$</sub>  antibody.

8. (Previously Presented) A method according to Claim 1 further comprising administering to the individual one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4.

9. (Currently Amended) A method according to Claim 8 wherein the antagonist of EP2 or EP4 is AH6809, an omega-substituted prostaglandin E derivative, AH23848B, AH22921X, IFTSYLECL (SEQ ID NO:7), IFASYECL (SEQ ID NO:8), IFTSAECL (SEQ ID NO:9), IFTSYEAL (SEQ ID NO:10), ILASYECL (SEQ ID NO:11), IFTSTDCL (SEQ ID NO:12), ~~TSYEAL XTSYEAL~~ (with where X is 4-biphenyl alanine) (SEQ ID NO:13), ~~TSYEAL XTSYEAL~~ (with where X is homophenyl alanine) (SEQ ID NO:14), a 5-thia-prostaglandin E derivative, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, or 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one.

10. (Original) Use of at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor, in the manufacture of a medicament for treating or preventing menorrhagia in a female individual.

11. (Original) Use according to Claim 10, wherein the individual is administered one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4.

12. (Previously Presented) Use of a combination of at least one agent that prevents PGF<sub>2 $\alpha$</sub> , having its effect on the FP receptor, and one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4, in the manufacture of a medicament for treating or preventing menorrhagia in a female individual.

13. (Original) Use of one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4 in the manufacture of a medicament for treating or preventing menorrhagia in a female individual, wherein the female individual is administered at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor.

14. (Original) A pharmaceutical composition comprising at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor for treating or preventing menorrhagia in a female individual.

15. (Original) A pharmaceutical composition according to Claim 14 further comprising one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4.

16. (Original) A vaginal ring or a tampon or an intrauterine device comprising at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor.

17. (Original) A vaginal ring or a tampon or an intrauterine device according to Claim 16 further comprising one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4.

18. (Previously Presented) A use according to Claim 10, wherein the agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor (i) prevents or reduces the binding of PGF<sub>2 $\alpha$</sub>  to the FP receptor, (ii) affects the interaction between PGF<sub>2 $\alpha$</sub>  and the FP receptor, or the interaction between the FP receptor and the associated G<sub>aq</sub> protein, thus inhibiting or disrupting a PGF<sub>2 $\alpha$</sub> -FP mediated signal transduction pathway, (iii) is an antagonist of the FP receptor, (iv) is an antagonist of PGF<sub>2 $\alpha$</sub> , or (v) is an anti-PGF<sub>2 $\alpha$</sub>  antibody.

19. (Currently Amended) Use according to Claim 11, wherein the antagonist of EP2 or EP4 is selected from the group of AH6809, an omega-substituted prostaglandin E derivative, AH23848B, AH22921X, IFTSYLECL (SEQ ID NO:7), IFASYECL (SEQ ID NO:8), IFTSAECL (SEQ ID NO:9), IFTSYEAL (SEQ ID NO:10), ILASYECL (SEQ ID NO:11), IFTSTDCL (SEQ ID NO:12), ~~TSYEAL XTSYEAL~~ (with where X is 4-biphenyl alanine) (SEQ ID NO:13), ~~TSYEAL XTSYEAL~~ (with where X is homophenyl alanine) (SEQ ID NO:14), a 5-thia-prostaglandin E derivative, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, or 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one.

20. (Original) A composition comprising at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor, and one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4.

21. (Original) A pharmaceutical composition comprising at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor, and one or more of an inhibitor of PGES and/or an antagonist of EP2 or EP4, and a pharmaceutically acceptable carrier.

22. (Original) A composition according to Claim 20 for use in medicine.

23. (Currently Amended) Use according to Claim 10 wherein the agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor is an antagonist of the FP receptor is selected from the group of any one or more of PGF<sub>2 $\alpha$</sub>  dimethyl amide; PGF<sub>2 $\alpha$</sub>  dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro PGF<sub>2 $\alpha$</sub> ); phloretin; glibenclamide; ridogrel; PHG113; PCP-1 (rvkfksqqhrqgrshhlem) (SEQ ID NO:1); PCP-2 (rkavlklnlyklasqccgvhvislhiwelssiknslkvaaisespvaeksast) (SEQ ID NO:2); PCP-3 (clseeakearrindeierqlrrdkrdarre-NH<sub>2</sub>) (SEQ ID NO:3); PCP-4 (kdttilqlnlkeynlv-NH<sub>2</sub>) (SEQ ID NO:4); PCP-8 (ilghrdyk) (SEQ ID NO:5); PCP-10 (wedrfyll) (SEQ ID NO:6); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).

24. (Previously Presented) A pharmaceutical composition according to Claim 14 wherein the agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor (i) prevents or reduces the binding of PGF<sub>2 $\alpha$</sub>  to the FP receptor, (ii) affects the interaction between PGF<sub>2 $\alpha$</sub>  and the FP receptor, or the interaction between the FP receptor and the associated G<sub>aq</sub> protein, thus inhibiting or disrupting a PGF<sub>2 $\alpha$</sub> -FP mediated signal transduction pathway, (iii) is an antagonist of the FP receptor, (iv) is an antagonist of PGF<sub>2 $\alpha$</sub> , or (v) is an anti-PGF<sub>2 $\alpha$</sub>  antibody.

25. (Currently Amended) A pharmaceutical composition according to claim 14 wherein the agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor is an antagonist of the FP receptor is selected from the group of any one or more of PGF<sub>2 $\alpha$</sub>  dimethyl amide; PGF<sub>2 $\alpha$</sub>  dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-

indanyl)-16,17,18,19,20-pantanor-5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro PGF<sub>2 $\alpha$</sub> ); phloretin; glibenclamide; ridogrel; PHG113; PCP-1 (rvkfksqqhrqgrshlem) (SEQ ID NO:1); PCP-2 (rkavlknlyklasqccgvhvislhiwelssiknslkvaaisespvaeksast) (SEQ ID NO:2); PCP-3 (clseeakearrindeierqlrrdkrdarre-NH<sub>2</sub>) (SEQ ID NO:3); PCP-4 (kdtlqlnlkeynlv-NH<sub>2</sub>) (SEQ ID NO:4); PCP-8 (ilghrdyk) (SEQ ID NO:5); PCP-10 (wedrfyll) (SEQ ID NO:6); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).

26. (Previously Presented) A vaginal ring or a tampon or an intrauterine device according to claim 16 wherein the at least one agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor (i) prevents or reduces the binding of PGF<sub>2 $\alpha$</sub>  to the FP receptor, (ii) affects the interaction between PGF<sub>2 $\alpha$</sub>  and the FP receptor, or the interaction between the FP receptor and the associated G<sub>αq</sub> protein, thus inhibiting or disrupting a PGF<sub>2 $\alpha$</sub> -FP mediated signal transduction pathway, (iii) is an antagonist of the FP receptor, (iv) is an antagonist of PGF<sub>2 $\alpha$</sub> , or (v) is an anti-PGF<sub>2 $\alpha$</sub>  antibody.

27. (Currently Amended) A vaginal ring or a tampon or an intrauterine device according to claim 16 wherein the agent that prevents PGF<sub>2 $\alpha$</sub>  having its effect on the FP receptor is an antagonist of the FP receptor is selected from the group of any one or more of PGF<sub>2 $\alpha$</sub>  dimethyl amide; PGF<sub>2 $\alpha$</sub>  dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pantanor-5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro PGF<sub>2 $\alpha$</sub> ); phloretin; glibenclamide; ridogrel; PHG113; PCP-1 (rvkfksqqhrqgrshlem) (SEQ ID NO:1); PCP-2 (rkavlknlyklasqccgvhvislhiwelssiknslkvaaisespvaeksast) (SEQ ID NO:2); PCP-3 (clseeakearrindeierqlrrdkrdarre-NH<sub>2</sub>) (SEQ ID NO:3); PCP-4 (kdtlqlnlkeynlv-NH<sub>2</sub>) (SEQ ID NO:4); PCP-8 (ilghrdyk) (SEQ ID NO:5); PCP-10 (wedrfyll) (SEQ ID NO:6); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).

28. (Currently Amended) A pharmaceutical composition according to Claim 15 wherein the antagonist of EP2 or EP4 is selected from the group of AH6809, an omega-substituted prostaglandin E derivative, AH23848B, AH22921X, IFTSYLECL (SEQ ID NO:7), IFASYECL (SEQ ID NO:8), IFTSAECL (SEQ ID NO:9), IFTSYEAL (SEQ ID NO:10), ILASYECL (SEQ ID NO:11), IFTSTDCL (SEQ ID NO:12), ~~TSYEAL XTSYEAL~~ (with where X is 4-biphenyl alanine) (SEQ ID NO:13), ~~TSYEAL XTSYEAL~~ (with where X is homophenyl alanine) (SEQ ID NO:14), a 5-thia-prostaglandin E derivative, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, or 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one.

29. (Currently Amended) A vaginal ring or a tampon or an intrauterine device according to claim 17 wherein the antagonist of EP2 or EP4 is selected from the group of AH6809, an omega-substituted prostaglandin E derivative, AH23848B, AH22921X, IFTSYLECL (SEQ ID NO:7), IFASYECL (SEQ ID NO:8), IFTSAECL (SEQ ID NO:9), IFTSYEAL (SEQ ID NO:10), ILASYECL (SEQ ID NO:11), IFTSTDCL (SEQ ID NO:12), ~~TSYEAL XTSYEAL~~ (with where X is 4-biphenyl alanine) (SEQ ID NO:13), ~~TSYEAL XTSYEAL~~ (with where X is homophenyl alanine) (SEQ ID NO:14), a 5-thia-prostaglandin E derivative, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, or 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one.